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1. Introduction 
Milk is thought to be the main source of biologically active compounds for infants, 
providing antibacterial and antiviral activities, facilitating nutrient absorption, promoting 
bone growth, enhancing immunological protection and supporting the development of host 
immune competence. In milk, the main categories of compounds related to antiviral activity 
through immune stimulation and suppression of host immune inflammation are the casein 
proteins, whey proteins and their derived peptides [1-3].  
Casein proteins, as well as casein fragments, function as antiviral and immune regulatory 
factors by regulating the innate immune response both through up-regulation to enhance 
killing of viruses, and down-regulation to reduce detrimental conditions such as sepsis [1, 3-
7]. Additionaly, caseins link the innate immune system to the adaptive immune system by 
activating and/or enhancing B- and T-cell mediated functions. The whey protein lactoferrin, 
and pepsin derived peptide fragments of this protein (e.g. lactoferricin) have been studied 
extensively for its antiviral properties [8-10] i.e. its direct interaction with the virus particle, 
interaction with cellular receptors on the target cells, and lately more complex antiviral 
mechanisms involving stimulation and regulation of the immune system have been 
discovered [2, 11-16]. Similarly, peptides tailored on specific protein fragments of casein and 
α-lactalbumin have also been investigated for their antiviral and immunomodulatory 
properties. Many of these studies have identified biologically active peptides that can 
prevent a viral infection, as well as regulate the immune status of the host [1, 2, 17-21]. 
Currently, some of these peptides are being investigated in clinical trials, like human 
lactoferrin fragment 1-11 (AM Pharma, Bunnvik, The Netherlands) [22] and LTX-302 (Lytix 
Biopharma, Tromsø, Norway) [20]. Moreover, another promising class of synthetic peptides 
with therapeutic potential is a group of innate defence regulator peptides, which exhibit 
immune protection by enhancing or suppressing the host immune response [23-26]. It is 
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tremendously encouraging that many of these proteins and peptides have pharmaceutical 
potential within antiviral and anticancer therapy, as vaccine adjuvants, as 
immunosuppressants for the treatment of autoimmune diseases and in conjunction with 
organ transplantation, etc. [20, 23-25, 27-29]. 
Studies have demonstrated that active milk protein and peptide compounds can be 
extracted from a variety of species including humans, bovine, porcine, mice and camel. The 
main focus in this paper is the antiviral and immune regulating properties (Table 1) of milk 
proteins (Table 2) and their peptide derived fragments (Table 3). The vast majority of the 
discussed studies deal with proteins and peptides of bovine origin, and these will be 
referenced with their protein names, while proteins and peptides from other origins will be 
explicitly specified with the species name. 
 
Virus Protein or peptide Model of antiviral function Reference 
Enveloped Virus 
Herpes simplex 
virus 1 
human and bovine 
lactoferrin and lactoferricin, 
lactoperoxidase
Binding to both virus particle 
and cellular receptors (heparan 
sulphate) to prevent viral 
adsorption and entry;  
Interference with intracellular 
replication events or synthesis 
of progeny viral components 
[9, 35, 55, 77-
79, 81-83] 
chemically modified milk 
proteins e.g. serum albumin, 
α-lactalbumin,  
β-lactoglobulin 
[89, 93, 99, 
100]  
Herpes simplex 
virus 2 
human and bovine 
lactoferrin 
Binding to virus receptor of 
non-GAG nature 
[10]  
-lactoglobuline Binding to virus particle  [93] 
Hepatitis C virus lactoferrin Binding to viral envelope 
protein E1 and E2 
[52, 63, 71, 
220] 
Hepatitis B virus iron- or zinc-saturated 
lactoferrin 
Binding to cellular molecules 
interfering with viral 
attachment/entry 
[47, 59]  
Hepatitis G virus lactoferrin Unknown [63] 
Respiratory syncytial 
virus 
lactoferrin, lactoperoxidase Binding to F1 subunit of RSV F 
protein to inhibit viral 
absorption 
[35, 44-46] 
Human 
immunodeficiency 
virus 
human and bovine 
lactoferrin, lactoperoxidase 
Binding to cellular receptor to 
inhibit viral absorption and 
replication 
[8, 18, 19, 34, 
48, 49, 62, 68, 
70]  
chemically modified milk 
proteins like serum albumin, 
α-lactalbumin, 
β-lactoglobulin 
[9, 89-92] 
Influenza virus 
(H3N2, H1N1 and 
H5N1)  
lactoferrin, κ-casein, 
glycomacropeptide, 
lactoperoxidase
Binding to hemagglutinin of 
virus 
[36, 53, 135] 
modified human serum [94, 101-103] 
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Virus Protein or peptide Model of antiviral function Reference 
albumin and  
β-lactoglobulin,  
α-lactalbumin, lactoferrin
Human 
cytomegalovirus 
lactoferrin and lactoferricin Interfere with virus target cells; 
up-regulation of killer cells; 
synergistic antiviral effect with 
cidofovir
[12-16]  
chemically modified milk 
proteins like serum albumin, 
α-lactalbumin,  
β-lactoglobulin
Binding to virus particle [12, 93, 96, 
221] 
Feline herpes virus 1 human and bovine 
lactoferrin
Binding to cellular molecules [54]  
Canine herpes virus human and bovine 
lactoferrin (apo- and holo-)
Binding to virus particle and 
cellular receptor on target cell
[74]  
Hantavirus lactoferrin Binding to cellular molecules; 
synergistic effect with Ribavirin 
on inhibiting viral replication 
[72, 122] 
Vesicular stomatitis 
virus 
lactoferrin Induction interferon-α/β 
expression to inhibit viral 
replication
[11] 
Friend virus 
complex 
human lactoferrin Regulation on the myelopoiesis; 
synergistic effect with 
interferon-γ
[11, 56, 57, 
64] 
Human 
papillomavirus 
human and bovine 
lactoferrin, 
human and bovine 
lactoferricin
Binding to heparan sulphate 
cell receptor  
[65, 121] 
Alphavirus heparan 
sulphate- adapted 
sindbis virus and 
semliki forest virus
human lactoferrin, charge-
modified human serum 
albumin 
Binding to heparan sulphate 
cell receptor  
[73]  
Severe acute 
respiratory 
syndrome 
coronavirus 
lactoferrin Binding to heparan sulphate 
cell receptor 
[120]  
Non-enveloped virus
Rotavirus human lactoferrin (apo-
/holo-), α-lactalbumin,  
β-lactoglobulin 
Binding to viral particles to 
prevent both rotavirus 
haemagglutination and viral 
binding to receptors on 
susceptible cells
[30, 40] 
human lactadherin Binding to structural protein of 
rotavirus and inhibits virus 
replication
[37, 38] 
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Virus Protein or peptide Model of antiviral function Reference 
high molecular glycoprotein 
(e.g. mucin) 
Inhibitor for viral-cell binding 
to prevent productive virus 
infection
[107, 108] 
immune globulin In vivo effect on inhibition of 
viral replication
[107] 
Poliovirus lactoferrin, modified bovine 
β-lactoglobulin
Binding to viral receptor on 
target cell
[50, 58, 104]  
Coxsackie virus modified bovine  
β-lactoglobulin 
Binding to viral receptor on 
target cell 
[104]  
Adenovirus lactoferrin Binding to viral protein III and 
IIIa; competition with virus for 
common membrane receptors
[60, 61, 69] 
Enterovirus (71, 
echovirus 6) 
lactoferrin Binding to both cellular 
receptors and the viral surface 
protein VP1
[51, 66, 67] 
Felin calicivirus lactoferrin Binding to cell receptor [50]  
Echovirus lactoferrin, lactoperoxidase Binding to cell receptor and 
viral structural proteins
[35, 75, 95] 
Table 1. Models of antiviral proteins & peptides from milk proteins 
2. Protein composition of milk and their antiviral activity  
There are in general two groups of proteins found in milk, casein and whey. The casein 
family accounts for approximately 80% of the protein mass and includes several types of 
casein, e.g. αs1, αs2, β and κ, which form micelle complexes in the water phase of milk. The 
whey proteins account for the remaining 20%, and include β-lactoglobulin (not present in 
human milk), α-lactalbumin, serum albumin, immunoglobulins, lactoferrin, transferring, 
and many minor proteins. Most of the whey proteins have been demonstrated to effectively 
prevent viral infection. For example, milk derived proteins including α-lactalbumin, β-
lactoglobulin, apo-lactoferrin (iron free), and homo-lactoferrin (Fe3+ carrying), were able to 
inhibit rotavirus attachment to cellular receptors by binding to the viral particle [30]. Among 
these proteins, apo-lactoferrin was proven to be the most active. Studies also showed that 
immunoglobulins of raw milk from non-immunized cows and camels, as well as from a 
commercially available bovine macromolecular whey protein fraction, have specific 
antibodies against human rotavirus, which are capable of inhibiting replication of 
rotaviruses in tissue culture and protect mice from infection in a murine model of rotavirus 
infection [31-33]. Lactoperoxidase, a haem-containing glycoprotein of the mammalian 
peroxidase family, is an important enzyme in the whey fraction of milk. In combination with 
its physiological substrates hydrogen peroxide and thiocyanate, lactoperoxidase manifests a 
wide spectrum of virucidal activities against human immunodeficiency virus, herpes 
simplex virus 1, respiratory syncytial virus and echovirus [34, 35]. Oral administration of 
lactoperoxidase also attenuate pneumonia in influenza virus infected mice through 
suppression of infiltration of the inflammatory cells in the lungs [36]. Furthermore, the 46kD 
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glycoprotein termed lactadherin, also known as milk fat globule-EGF factor 8 protein, 
inhibited rotavirus binding to cellular receptors (acetylneuraminic acid and/or integrin) on 
target and/or specifically interacting with viral structural glycoprotein VP4 of rotavirus, 
blocking host-pathogen interaction [37-40].  
Lactoferrin, first isolated in 1960 from both human [41, 42] and bovine milk [43], has been 
demonstrated to exhibit antiviral activity against many viruses [8, 10-16, 18, 19, 40, 44-74] 
(Table 2). Most studies indicate that lactoferrin and its derived peptides are likely to 
interfere in the virus host cell interaction (Figure 1). For example it has been demonstrated 
that lactoferrin is able to bind both viral receptor and the viral surface protein VP1 on 
enterovirus (enterovirus 71 and echovirus 6), thus interfering with viral entry [51, 66, 67, 75, 
76]. Similarly, both apo- and holo-lactoferrin has been demonstrated to interact both with 
canine herpes virus and surface receptors on the Madin-Darby canine kidney cells, thus 
inhibiting canine herpes virus infection [74]. With regard to the anti-herpes simplex virus 1 
ability of lactoferrin, both bovine and human lactoferrin and lactoferricin have 
demonstrated the ability to block viral entry and also inhibit viral cell-to-cell spread in a 
dose dependent manner [55, 77-79], through interaction with negatively charged 
glycosaminoglycans like heparan sulphate on the cell surface [55, 80-83] and elements of the 
viral particle [55]. Differently from herpes simplex virus 1, Marchetti et. al. found that 
lactoferrin inhibited herpes simplex virus 2 plaque forming activity also in cells without 
glycosaminoglycans suggesting that lactoferrin might block one of the specific herpes 
simplex virus 2 entry receptors [10]. 
Many of the traditional entry blocking effects observed by lactoferrin involve electrostatic 
interaction with anionic heparan sulphate molecules on the host cell surface [82]. The ability 
to interact with anionic heparan sulphate is maybe not that surprising, when evaluating the 
three dimensional structural composition of lactoferrin, demonstrating a rather striking 
cationic patch on the N-terminal lobe of the molecule [84] (Figure 1). Similarly, other highly 
cationic peptides have also been demonstrated to effectively interfere with herpes simplex 
virus attachment and entry [80, 85].  
Conversely, several other milk proteins i.e. β-lactoglobulin [86], α-lactalbumin [87] are 
described with anionic patches on their surfaces, while the casein homologues like αs2-
casein [88] have both specific anionic and cationic patches on the surface (Figure 1). Thus, 
charge modification of milk proteins may increase their ability to interfere with virus host 
cell interactions. 3-hydroxyphthalic anhydride modification of human and bovine serum 
albumin, and bovine β-lactoglobulin, increased the proteins negative charges in addition to 
their ability to prevent interaction between human immunodeficiency virus 1 envelope  
glycoprotein gp120 and the CD4 host cell receptor, by direct interaction and blocking of the 
CD4 receptor [89, 90]. Similar effects have also been observed for 3-hydroxyphthalic 
anhydride modified α-lactalbumin and αs2-casein, as well as for maleylated- and 
succinylated-human serum albumin, indicating that human immunodeficiency virus 
inhibition was a general property of negatively charged polypeptides [9, 91, 92]. Among the 
inhibitory proteins, 3-hydroxyphthalic anhydride β-lactoglobulin also demonstrated a broad 
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spectrum activity affecting herpes simplex virus 1 and 2 in addition to human 
cytomegalovirus by binding to the virus particles, inhibiting particularly the binding of 
monoclonal antibodies towards glycoprotein E and glycoprotein C [93]. Comparative results 
have been shown for anionic-modified human serum albumin and β-lactoglobulin which 
prevents influenza virus membrane fusion with the host cell membrane, a process mediated 
by the viral glycoprotein hemagglutinin [94]. Interestingly, this anti-influenza effect has not 
been observed for other milk proteins carrying negative charges, like succinylated bovine 
serum albumin, lactalbumin, lactoferrin, lysozyme and transferrin [94]. It is said that 
inhibition of viral fusion demonstrates a certain degree of specificity for negative charged 
proteins. However, addition of net negative charges to lactoferrin by acylation with either 
succinic- or acetic anhydride abolished its anti-poliovirus and anti-feline calicivirus activity, 
which may be attributed to the obliterate binding of acylated lactoferrin to the surfaces of 
susceptible cells [95]. Also, when negatively charged groups were added to lactoferrin by 
succinylation, the antiviral effect on human immunodeficiency virus 1 was increased, but 
the antiviral potency against human cytomegalovirus was mostly decreased [96], illustrating 
the proteins different modes of action. Similar results were also obtained by Florisa et. al. 
which demonstrated a stronger antiviral effect against human immunodeficiency virus by 
developing poly-anionic milk proteins, while stronger effects could be obtained against 
human cytomegalovirus by creating poly-cationic milk proteins [12].  
  
Figure 1. The traditional direct antiviral mechanismes of selected milk proteins. Several proteins are 
characterized to interact directly with cell surface heparan sulphate, like lactoferrin (1) and 
lactoperoxidase. Casein species like -casein (3) and s2-casein (4) are despite high cationic character on 
their surface not described to interact with heparan sulphate, and the latter in stead been demonstated to 
interact with the virus pareticle. Anionic milk proteins like -lactalbumine (5) and -lactoglobuline (6) are 
also illustrated to interact directly with the virus particle, thus preventing host receptor interaction.  
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Source Protein % of whey 
protein 
% of 
casein 
Molecular 
size (kDa) 
Nature PDB code 
Whey  β-lactoglobulin 50-55 NA ～18.4 Apolipoprotein 1DV9 
α-lactalbumin 20-25 NA ～14.1 Albumin 1A4V 
Immunoglobulins 10-15 NA ～150 Glycoprotein ﹉ 
Lactoferrin 1-2 NA ～80 Glycoprotein 1BLF 
Lactoperoxidase 0.5 NA ～70 Glycoprotein 3GC1 
Serum albumin 5-10 NA ～66 Albumin  
Glycomacropeptide 10-15 NA --- Phosphoprotein  
Casein  αs1-casein NA 40-50 ～23 Phosphoprotein  
αs2-casein NA 10-15 ～23 Phosphoprotein 1NA7 
β-casein NA 30-35 ～24 Phosphoprotein  
κ-casein NA 10-15 ～19 Phosphoprotein  
γ-casein NA 5-10 ～75-100 Phosphoprotein 2CHL 
Note. The PDB extention codes are for crystal structure files for the respective milk proteins. The structures have been 
used when generating the graphic illustration on figure 1.  
Table 2. Bioactive proteins from bovine milk. 
The strong antiviral activity of poly-cationic compounds is generally explained by the 
compounds ability to interact with anionic heparan sulphate on the host cell surface, which 
works as a broad spectrum attachment receptor for several viruses [97, 98]. Thus, it is not 
surprising that methylated or ethylated α-lactalbumin and β-lactoglobulin demonstrate 
antiviral activity against the bacteriophage M13 through the inhibition of the phage DNA 
replication, as well as against herpes simplex virus 1 replication, with increasing activity 
proportional to the extent of esterification or increased basicity of the modified proteins [99, 
100]. The net positive charge-modified human serum albumin had a similar antiviral effect 
as lactoferrin, against heparan sulphate adapted sindbis virus and semliki forest virus, by 
blocking the virus receptor on the cell surface, indicating that the antiviral activity of 
lactoferrin mainly is related to its net positive charge [73]. Methylated α-lactalbumin, β-
lactoglobulin and lactoferrin also demonstrate enhanced antiviral activity against human 
influenza virus A subtype H3N2 and subtype H1N1 [101, 102], and lethal avian influenza A 
(H5N1) [103]. This effect is most likely linked to the disruption of the electrostatic 
interactions within hemagglutinin, by the esterified whey proteins, thus affecting the 
proteins stability and capacity to trigger envelope fusion with the host cell. Furthermore, 
methylation of β-lactoglobulin does also enhance the proteins antiviral activity against 
coxsackie virus and poliovirus type 1 in a dose dependent manner [104]. This illustrates that 
chemically modified whey proteins with added negative or positive charges can exert 
increased antiviral effect against a diverse group of viruses, through different antiviral 
mechanisms. The virucidal activity of the modified milk proteins, with additional negative 
charges, may attribute to a stronger interaction of these proteins with the viral envelope 
proteins. Esterification of whey proteins with methanol or ethanol would increase their 
cationic charge, thus increasing their affinity for negatively charged macromolecules such as 
host cell receptors and viral DNA or RNA, thus inhibiting viral attachment to cellular 
 
Milk Protein 52 
membranes or inhibiting viral replication and transcription, respectively. The structural 
differences between enveloped and non-enveloped viruses in addition to the unique protein 
composition in milk from different species preclude a generalized conclusion of the milk 
proteins potential. Thus, further studies should be carried out to identify the underlying 
molecular interactions involved, and the true therapeutic potential of these milk derived 
molecules. 
3. Traditional antiviral mechanisms of milk-derived proteins  
The life cycle of a virus comprises several phases such as binding to the host cell surface, 
entry or fusion, replication of the viral genome, viral protein synthesis, virus progeny 
assembly and release. All these steps may be targeted by antiviral agents or milk derived 
proteins. 
Binding to structural virus proteins prevent virus host cell interaction. For the non-enveloped 
viruses, structural proteins on the surface of the virion protruding as spikes, such as 
glycoprotein VP4 of rotavirus [105] or fibers associated with each penton base of the capsid 
on for example adenovirus [106]. These proteins recognize host cell surface receptors, and 
are involved in facilitating the initial virus to host cell attachment. Enveloped viruses, 
meaning the viral capsid is coated with a lipid membrane known as the viral envelop, infect 
host cells via the interaction between envelop proteins and cellular receptors. The envelop 
proteins include E1 and E2 of hepatitis C virus, F protein of respiratory syncytial virus, 
hemagglutinin of influenza viruses, etc.  
Many of the antiviral milk proteins can bind to structural proteins of the virion in order to 
prevent binding of the virus to the target cell and subsequently inhibit entry of the viral 
genome into the host cell. Human lactoferrin (apo- or Fe3+), α-lactalbumin, β-lactoglobulin, 
human lactadherin, mucin, and immunoglobulin from milk could prevent rotavirus 
infection through the binding to structural viral protein VP4 [30, 37, 38, 40, 107, 108]. Also, 
the antiviral activity of lactoferrin against adenovirus has been attributed to the interaction 
of the milk protein with viral capsid proteins [60, 61, 69]. 
Furthermore, Ikeda et. al. has also demonstrated that lactoferrin effectively protect against 
hepatitis C virus infection in hepatocytes and lymphocytes by neutralizing the virus, while a 
basic N-terminal loop of lactoferrin named lactoferricin exhibited no antiviral properties in 
the same experiments [63]. Lactoferrin has also been demonstrated to inhibit the absorption 
and growth of respiratory syncytial virus in cell culture through direct interaction with the 
F(1) subunit of the viral F protein, which is the most important surface glycoprotein 
participating in viral penetration [44, 45]. Blocking of viral entry like this, leads to down-
regulation of respiratory syncytial virus induced interleulin-8 secretion from the HEp-2 
cells, which consequently leads to a dampening of the immune response as the low levels of 
interleukine-8 is inadequate to recruit neutrophils to phagocytose the viral antigen [46]. 
Hemagglutinin is an antigenic glycoprotein found on the surface of influenza viruses. The 
glycoprotein has two main functions; recognition of target cells through the binding of sialic 
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acid-containing receptors and facilitating entry of the viral genome into the target cells by 
initiating fusion of host endosomal membrane with the viral membrane. Thus, targeting the 
hemagglutination activity of hemaglutinin could be a robust mechanism in fighting 
influenza virus infections. Influenza hemaglutinin has also successfully been targeted by 
both human and bovine lactoferrin (apo- and holo-), as well as κ-casein glycomacropeptide, 
reduce viral hemagglutination [30, 53]. Moreover, the addition of methylated β-lactoglobulin 
in the medium of Madin-Darby canine kidney cell lines infected with influenza virus H1N1 
reduced hemagglutination in a concentration-dependent manner [101]. 
Interference with viral entry, through virus and/or cell surface interaction. Viruses recognize and 
conjugate to specific host cell receptors. These receptor molecules are mainly of protein 
nature, including glycoprotein, lipoprotein and glycolipid-protein. Hence, host cell 
specificity or preference is guided by the level of expression of these individual receptor 
molecules on the different cells. For example, the main goal of human immunodeficiency 
virus is to infect CD4+ T-lymphocytes and initiate replication of a large number of progeny 
virions. However, the initial infection with this virus is usually of epithelial dendritic cells, 
which then are used for transport to the lymph nodes. Human immunodeficiency virus 
attachment to for example emigrating dendritic cells, is mediated by the successive 
interactions of the viral envelop glycoprotein gp120 with CD4 (a glycoprotein known as 
cluster of differentiation 4) and a co-receptor, CXCR4 (C-X-C chemokine receptor type 4, 
also known as fusin or CD184) or CCR5 (C-C chemokine receptor type 5, also known as 
CD195) [109-111]. However, in cells like macrophages and skin dendritic cells that are 
lacking or weakly expressing CD4, many other cell surface molecules such as heparan 
sulphate proteoglycans [112, 113], mannose receptor [48, 114], or dendritic cells-specific 
intracellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) [62, 109] can play a key 
role in the initial multistep interaction between the virus and host cell surface. Consequently, 
one might hypothesis that human immunodeficiency virus entry into the host cell might be 
efficiently inhibited via the interaction between antiviral milk proteins from bovine or human 
sources and some of the receptors described above. This has also been demonstrated to be 
true, for lactoferrin which effectively can bind heparan sulphate as well as mannose receptor 
like nucleolin, both which will inhibit virus attachment [18, 48]. Other studies have also 
indicated that a peptide fragment (hLF1-33) of human lactoferrin (residue 1-33) constituting 
the glycosaminoglycan recognizing site of the human lactoferrin, exhibit inhibitory effect on 
human immunodeficiency virus 1 attachment to epithelial cells, though its activity was lower 
as compared to the native protein [19]. Interestingly however, hLF1-33 had no inhibitory effect 
on transferring human immunodeficiency virus 1 from immature dendritic cells to CD4 T-
lymphocytes, but enhancing virus transmission in contrast to human lactoferrin. This may 
suggest that the hLF1-33 exposed domain is not involved in human lactoferrin associated 
inhibition of human immunodeficiency virus 1 transfer to CD4 T-cells [19]. Moreover, bovine 
lactoferrin could bind strongly to DC-SIGN to prevent human immunodeficiency virus 1 
capture and subsequent transmission on dendritic cells, and bovine lactoferrin was a much 
more efficient inhibitor than human lactoferrin on blocking not only dendritic cell mediated 
human immunodeficiency virus 1 transmission to - but also replication in CD4 T-cells [49].  
 
Milk Protein 54 
Although it has been identified that a metallopeptidase, angiotensin-converting enzyme 2, is 
a functional receptor for severe acute respiratory syndrome coronavirus infection [115], 
other reports have demonstrated that DC-SIGN, L-SIGN (also called CD209L, specific for 
liver/lymph node) [116-119], and heparan sulphate [120] also are involved in the virus 
pathogenesis. Thus, there are reasons to believe that lactoferrin could prevent severe acute 
respiratory syndrome coronavirus spread in the host through the same mechanism as 
described for human immunodeficiency virus, by interacting with DC-SIGN or heparan 
sulphate receptors. Recently, Lang et. al. also described that lactoferrin curtailed the entry of 
severe acute respiratory syndrome coronavirus into HEK293E/ angiotensin-converting 
enzyme 2-Myc cells by binding to heparan sulphate [120]. 
Human papillomavirus can also use heparan sulphate on the target cell surface as a 
receptor. Thus, by incubating HaCaT cells and papillomavirus 16 virus like particles with 
human and bovine lactoferrin Drobni et. al. have confirmed that human papillomavirus 
entry can be inhibited by lactoferrin in a dose-dependent fashion [65]. Subsequently, they 
also demonstrated that bovine lactoferrin peptide (bLF17-33) region 17-33 was a more 
potent inhibitor of both human papillomavirus 5 and 16 pseudovirus infection than the 
native protein, while human lactoferricin (hLF1-49) region 1-49 from human lactoferrin, 
showed modest antiviral activity against the same viruses and bLF17-42 prevented only 
papillomavirus 5 pseudovirus infection. With regard to the viral attachment, only hLF1-49 
and bLF17-42 exhibited antiviral effect [121].  
In a classical pre-incubation study on Vero E6 cells, it was demonstrated that lactoferrin had 
enhanced antiviral activity against hantavirus infection when added prior to infection. 
However, this boost in activity could be removed if the cells were subsequently washed with 
phosphate buffered saline prior to infection [72, 122]. These results might be explained by the 
weak interaction between lactoferrin and other cellular molecules rather than heparan 
sulphate, as the interaction between lactoferrin and heparan sulphate should withstand 
phosphate buffered saline washing [80]. Further research should be developed to identify 
whether β3 integrin and/or β1 integrin molecules are binding to lactoferrin [123-125]. 
Similarly, using indirect immunofluorescence, McCann et. al. found that bovine lactoferrin 
could bind to Crandell-Reese feline kidney cells used for propagation of feline calicivirus, as 
well as Monkey Embryo kidney cells used with poliovirus, indicating that the interference 
of viral infection might be attributed to lactoferrin binding to the cellular receptor on the 
respective cells, though the related cell receptors for feline calicivirus and poliovirus have 
not yet been identified [50]. Contradicting this, it was demonstrated that lactoferricin 
decreased feline calicivirus but not poliovirus infection. Moreover, feline herpes virus-1 
replication could be prevented by exposing cultured Crandell-Reese feline kidney cells to 
lactoferrin prior to or during viral adsorption, but not following viral adsorption, suggesting 
that the inhibitory effect on feline herpes virus 1 adsorption to the cell surface and/or viral 
penetration into the cell might be related to the interaction between lactoferrin and cellular 
receptor on the Crandell-Reese feline kidney cells [54]. 
Interference with certain viral enzymes required for virus replication. The process of viral 
replication will involve a myriad of enzymes, such as DNA- or RNA-polymerases, reverse 
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transcriptase, integrase, etc. The necessity of viral enzymes for viral replication means that 
interference with any of them potentially could result in a selective antiviral mode of action. 
Ng et. al. has assayed the inhibitory effect of proteins from bovine milk on the crucial 
enzymes for the human immunodeficiency virus type 1 life cycle [126]. They demonstrated 
that lactoferrin strongly inhibited reverse transcriptase but only slightly inhibited the viral 
protease and integrase. In parallel, α-lactalbumin, β-lactoglobulin and casein were 
demonstrated to affect human immunodeficiency virus protease and integrase, while not 
affecting the reverse transcriptase [126]. 
4. Modulation of innate immune responses - A novel antiviral strategy 
The immune system consists of the innate and the adaptive branch, which exerts its 
functions through recognition of foreign pathogen resulting in a series of responses to 
eliminate the infectious material. Both innate leukocytes (including macrophages, dendritic 
cells, and natural killer cells) and adaptive immune cells (B-cells and T-cells) are involved in 
host immune protection and bridging these two pathways is a variety of traditional signal 
molecules (cytokines and chemokines). Recently it has also been documented that natural 
occurring host defence peptides (and proteins) are involved in the orchestration of a well 
balanced and effective immune response [127-129]. Lactoferrin is one such host defence 
protein, and it has been demonstrated that lactoferrin can increase the cytotoxic functions of 
natural killer cells and lymphokine-actived killer cells especially in infants, which normally 
have low activity in these cell populations [130]. Lactoferrin can also enhance the mobility of 
polymorphonuclear leucocytes and increase the production of superoxide [131], activate 
macrophages and stimulate the release of both pro- and anti-inflammatory cytokines, i.e. 
interleukin-1,-6,-8,-18, interferon-γ and tumor necrosis factor-α [132]. The antiviral effect of 
lactoferrin on cytomegalovirus in a murine infection model has been demonstrated to be a 
result of augmentation of natural killer cell activity rather than of the cytolytic T-lymphocytes 
[14]. Similarly, human lactoferrin has also been proven to have an effect on natural killer cell 
cytotoxicity against haematopoietic and epithelial tumor cells [133].  
Furthermore, the antiviral activity of lactoferrin against vesicular stomatitis virus has been 
related to its capacity of up-regulating the accumulation of interferon-β in peritoneal 
macrophages from mice [11]. Another experiment with interperitoneal administration of 
lactoferrin to CBA mice demonstrated enhanced production of tumor necrosis factor-α and 
interleukin-12. Similar results were also reported after in vitro stimulation of J774A.1 murine 
macrophages by lactoferrin [134]. Increased expression of interleukin-12, in addition to 
interferon-β and NOD2, were also observed in mice that were administered lactoferrin 
orally after being infected with influenza virus, thus suggesting that lactoferrin potentially 
can promote systemic host immunity [135]. As an important inductor of interferon-γ 
production in T-cells and natural killer cells, interleukin-12 exhibited a marked synergism 
with interferon-γ in activating monocytes and macrophages, promoting the differentiation 
of B-cells and T-cells, and increasing the induction of major histocompatibility complex I 
and II molecules by up-regulating expression of the interleukin-18 receptor on cells 
producing interferon-γ [136-138]. 
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With regard to modulation of the adaptive immune system, lactoferrin could exert higher 
growth stimulatory activity on lymphocytes than transferrin [139], induce phenotypic 
changes of immature B- and T-cells from newborn or chromosome X-linked 
immunodeficient mice, as well as enable B-cells to present antigen to an antigen-specific T-
helper type 2 cell line [140, 141]. Immature B-cells cultured with lactoferrin will also increase 
their ability to promote antigen-specific T-cell proliferation, indirectly indicating enhanced 
B-cell antigen presentation [140]. 
In summary, the effects of lactoferrin on the activation, maturation, migration and antigen 
presentation of the innate and adaptive immune cells, suggest that lactoferrin have the 
potential to associate the cellular functions and responses of the innate and adaptive 
immune cells, respectively. The modulating effects of lactoferrin on cytokine levels, 
especially of interleukin-12 and interleukin-18 illuminates the milk proteins role in 
connecting the innate and adaptive immune response.  
5. Milk derived peptides as immune modulators 
There is a great quantity of milk proteins and peptides other than lactoferrin that can lead to 
immune regulation, involving in both up- and down-regulation of the immune system. 
Peptides from casein [4, 6, 142], β-lactoglobulin [143, 144], and α-lactalbumin [7] also 
enhance and/or suppress immune cell function (Table 3). 
 
Precursor 
protein 
Fragment Peptide sequence Name Function Reference 
αs1-casein 23-27 FFVAP α-casokinin-5 ACE-inhibition [222, 223] 
28-34 FPEVFGK α-casokinin-7 ACE-inhibition [222] 
23-34 FFVAP FPEVFGK ACE-inhibition [224] 
104-109 YKVPQL ACE-inhibition [225] 
158-162 YVPFP αs1-
casomorphin 
Opioid agonist, 
immunomodulation 
[159, 226] 
169-193 LGTQYTDAPSFSDIPNPIGSENSEK ACE-inhibition [227] 
194-199 TTMPLW α-casokinin-6 ACE-inhibition, 
immunostimulatory 
activity 
[5, 228] 
201-212 IGSENSEKTTMP ACE-inhibition [229] 
αs2-casein 94-103 QKALNEINQF ACE-inhibition [166] 
163-176 TKKTKLTEEEKNRL ACE-inhibition [166] 
β-casein 1-25 RELEELNVPGEIVES
(P)LS(P)S(P)S(P)EESITR 
casein 
phosphopeptide
Immunostimulatory 
activity 
[3]  
54-59 VEPIPY Immunostimulatory 
activity 
[6, 149] 
60-66 YPFPGPI β-
casomorphin-7 
ACE-inhibition, 
immunomodulation 
activity 
[1, 230, 
231] 
63-68 PGPIPN Immunomodulation [6, 232] 
60-70 YPFPGPIPN β-
casomorphin-11 
Immunostimulatory 
activity, opioid and 
ACE-inhibitory 
activities 
[233] 
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Precursor 
protein 
Fragment Peptide sequence Name Function Reference 
73-89 NIPPLTQTPVVVPPFIQ ACE-inhibition [229]  
114-118 YPVEP β-
casochemotide-1
Promote innate host 
immune response 
[142] 
124-133 MPFPKYPVEP ACE-inhibition [229] 
169-175 KVLPVPQ ACE-inhibition [225, 229] 
177-183 AVPYPQR β-casokinin-7 ACE-inhibition [223] 
191-193 LLY Immunomodulation 
activity 
[6, 234] 
193-202 YQQPVLGPVR β-casokinin-10 ACE-inhibition, 
immunostimulatory 
activity 
[1] 
210-221 EPVLGPVRGPFP ACE-inhibition [229] 
κ-casein 108-110 IPP ACE-inhibition [235] 
106-116 MAIPPKKNQDK casoplatelin Antithrombotic activity [236] 
 YIPIQYVLSR Casoxin C Opioid agonist [237] 
 YPSY Casoxin 4 Opioid agonist [238] 
α-
lactalbumin 
18-20 YGG Immunomodulation [1] 
50-53 YGLF α-lactorphin ACE-inhibition [143, 144] 
99-108 LDDDLTDDI ACE-inhibition [239] 
104-108 LTDDI ACE-inhibition [239] 
β-
lactoglobulin 
22-25 TMKG ACE-inhibition [239] 
32-40 AGTWYSLAM ACE-inhibition [239] 
94-100 IPAVFKI ACE-inhibition [239] 
106-111 NKVLVL ACE-inhibition [239] 
102-105 YLLF β-lactorphin ACE-inhibition [143, 144] 
142-148 ALPMHIR ACE-inhibition [240] 
Bovine serum 
albumin 
399-404 YGFQNA serorphin Opioid [241]  
208-216 ALKAWSVAR albutensin A ACE-inhibition [242] 
Bovine 
lactoferrin 
17-41 FKCRRWQWRMKKLGAPSITCVRRAF lactoferricin Anti-herpes simplex 
virus activity, ACE-
inhibition, 
immunomodulation 
activity 
[2, 80] 
17-26 FKCRRWQWRW immunomodulation 
activity 
[21] 
Human 
lactoferrin 
1-49 GRRRRSVQWCAVSQPEATKCFQWQR
NMRKVRGPPVSCIKRDSPIQCI 
lactoferricin Anti-herpes simplex 
virus activity 
[80] 
1-32 GRRRRSVQWCAVSQPEATKCFQWQR
NMRKVRGP 
LF-33 (human) Anti-human 
immunodeficiency virus 
activity 
[18, 19] 
222-230; 
264-268 
ADRDQYELL;
EDLIWK 
Inhibit herpes simplex 
virus 1 infection 
[243] 
268-284 KWNLLRQAQEKFGKDKS Lactoferrampin Immunomodulation 
activity 
[148] 
318-323 YLGSGY Lactoferroxin A Opioid agonist [244] 
536-540 RYYGY Lactoferroxin B Opioid agonist [244] 
673-679 KYLGPQY Lactoferroxin C Opioid agonist [244] 
 
Note: ACE-inhibition, Angiotensin-converting enzyme-inhibition.  
Table 3. Milk proteins-derived peptides with antiviral and immunemodulatory activity 
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Up-regulation of immune system. Bovine and human lactoferricin, from N-terminal end of 
bovine and human lactoferrin, respectively, are known for their ability to improve and 
modulate the function of host immune system [145-147]. Additional, deletion fragments of 
lactoferrin like the peptide sequence FKCRRWQWRW, corresponding to N-terminal 
fragment 17-26 of bovine lactoferrin, has demonstrated potent activation of 
polymorphonuclear leukocytes [21]. Another lactoferrin derived peptide termed 
lactoferrampin, containing residues 268-284 from the N-terminal domain of lactoferrin, is 
located in close proximity to the cationic lactoferricin sequence, in the three dimensional 
structure. Lactoferrampin has been shown to exhibit antimicrobial activity and can 
improving immune function and gut health in the present of lactoferricin. Dietary 
supplementation of piglets with an expressed fusion peptide composed of bovine 
lactoferricin linked to lactoferrampin demonstrated the ability to increased serum levels of 
IgA, IgG, and IgM, while decreasing the incidence of diarrhea in the piglets [148]. 
Immunomodulating casein peptides have been found to stimulate the proliferation of 
human lymphocytes and the phagocytic activities of macrophages [4]. Casein 
phosphopeptides from fermented milk products, such as plain yogurts and cheeses, has 
shown beneficial effects on the immune system including the mitogenic effect and IgA 
enhancing effect in mouse spleen cell cultures [3]. According to the results of other studies, 
human β-casein fraction 54-59 has demonstrated to enhance the phagocytic activity of 
macrophages both in mice and humans and increase resistance against certain bacteria in 
mice [6, 149]. 
Chemotactic factors in the tissue do also play an essential role in host defence against 
microbial infection by inducing leukocyte infiltration. A pentapeptide (β-casochemotide-1) 
with amino acid sequence (YPVEP) matching an actinase E digest peptide from bovine β-
casein (corresponding to fraction 114-118), has been tested and demonstrated to both 
chemoattract and activate, human and mouse monocytes and macrophages by using a 
unique G-protein coupled receptors [142]. 
In addition, Colostrinin, also known as PRP, is a naturally occurring mixture of proline-rich 
polypeptides derived from colostrums and it can stimulate the immune response in animal 
and in vitro studies by causing differentiation of murine thymocytes into functionally active 
T-cells [150], as well as inhibit autoimmune disorders. Subsequent studies have shown that 
Colostrinin largely consists of the peptides derived from proteolytic processing of the milk 
proteins β-casein and β-casein homolog’s [151]. Among the Colostrinin digestion peptides 
are an active nona-peptide fragment VESYVPLFP demonstrating a full spectrum of 
biological activities [150]. Furthermore, fermentation of milk by Lactobacillus helveticus has 
also proven to generate novel peptide fragments, i.e. three derived from β-casein and one 
peptide from α-lactalbumin, and the peptides have demonstrated the ability to stimulate the 
production of tumor necrosis factor-α and modulate macrophage activity [7]. 
Down-regulation of immune responses. It has been demonstrated that a modified whey protein 
concentrate, developed as a by-product from commercial manufacturing of cheese, not only 
suppress B- and T-lymphocyte proliferating responses to mitogens in a dose-dependent 
fashion, but also suppress alloantigen-induced lymphocyte proliferation during a mixed 
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leukocyte reaction. Moreover, the modified whey protein concentrate could also have been 
demonstrated to suppress other indices of lymphocyte activation, e.g. cytokine secretion and 
the formation of activated (CD25+) T-cell blasts, showing that the mechanism of suppression 
may be related to an inhibition of the lymphocyte activation process. However, the 
interleukin-2 cytokine-mediated response was not affected by the presence of the modified 
whey protein concentrate in culture [152]. Similarly, intact -casein and -
caseinoglycopeptide (fragment 106-169), which have been prepared from -casein digested 
with rennin, in addition to a commercial whey protein concentrate, all significantly inhibit 
the mitogen-induced proliferative response of mouse spleen lymphocytes and Peyer’s patch 
cells [153-155]. As a result of this it has been proposed that -caseinoglycopeptide fragment 
106-169 can inhibit the phytohaemagglutinin induced proliferation of mouse splenocytes via 
at least two different models; production of an inhibitory component that reacts with the 
anti-interleukin-1 antibody or through suppression of interleukin-2 receptor expression on 
CD4+ T-cells [156].  
The opioid system plays a major role in immune modulation, both through classical opioid 
receptor, but also through other mechanisems. For example, opioid peptides have been 
demonstrated to inhibit phagocytosis [157], decrease natural killer cell number and activity 
and decrease cell-mediated hypersensitivity [158]. Also, αs1-casomorphin, an opioid 
agonist, can modulate antibody and cytokine secretion by multiple myeloma cells in a cell 
line-dependent and opioid receptor-independent manner, but it was shown to decrease the 
antibody secretion by normal B-lymphocytes and the proliferation rate of multiple myeloma 
cells through opioid receptor activation [159]. In other words, there might be two different 
opioid mechanisms, mediated by parallel signalling pathways, i.e. one early non-opioid 
receptor related effect modulating the constitutive secretion of immunoglobulin and 
cytokine, as well as a second long lasting receptor-mediated action of cell growth. Thus, 
opioids might be employed in controlling the humoral immunity. 
Furthermore, the rennin-angiotensin-aldosterone system is not only a major regulator of 
blood pressure; it also plays a key role in autoimmunity. The angiotensin peptide (AII), is 
one component of the rennin-angiotensin-aldosterone system, and has direct activity on T-
cell function, including activation, expression level of tissue-homing markers and 
production of tumor necrosis factor-α [160]. Inhibitors of angiotensin-converting enzyme 
will dampen the proteolytic process of the larger angiotensin peptides (AI) to the active AII. 
Thus, inhibition of T-cell angiotensin-converting enzyme blocks production of tumor 
necrosis factor-α, which modulates the proliferation of human immunodeficiency virus 
[161] and regulates the helper activity in B-cell activation [162]. This will also suppress the 
auto-reactive T-helper 1 and T-helper 17 cells and promotes antigen-specific CD4+FoxP3+ 
regulatory T-cells through inhibition of the canonical NF-κB1 transcription factor complex 
and activation of the alternative NF-κB2 pathway [163]. Moreover, angiotensin-converting 
enzyme inhibitors play a pivotal role in immune defence by decreasing the degradation of 
bradykinin and enkephalin [4, 164].  
A variety of angiotensin-converting enzyme inhibitory peptides have been found in the 
hydrolysates of milk using different enzymes; the bovine αs1-casein (fragment) f24-47, f104-
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109, f169-193, f194-199 and f201-212, αs2- casein f94-103 and f163-176, β-casein f60-66, f60-70, 
f169-175, f177-183 and f193-202, α-lactalbumin f18-20 and f50-53; β-lactoglobulin f102-105 
and f142-148, bovine serum albumin f208-216, lactoferrin f17-41 (Table 3). Among all these 
angiotensin-converting enzyme inhibitors, it should be emphasised that peptides αs1-casein 
f194-199, β-casein f60-66 and f193-202 have shown to have both angiotensin-converting 
enzyme inhibitory activities and immune stimulatory effect. 
Moreover, recombinant human αs1-casein expressed in Escherichia coli has been purified and 
digested with trypsin in an attempt to find peptides with angiotensin-I-converting enzyme 
inhibitory activity. Three novel angiotensin-converting enzyme inhibitory peptides, A-II, B-
II and C, have been isolated and their amino acid sequences identified as YPER (residues 8-
11), YYPQIMQY (residues 136-143) and NNVMLQW (residues 164-170), respectively [165]. 
Two other sequences QKALNEINQF and TKKTKLTEEEKNRL from bovine milk αs2-casein 
have even stronger inhibitory effects on the angiotensin-converting enzyme [166]. 
Regardless, no structure-function relationship study for milk-derived peptides in respect to 
their angiotensin-converting enzyme inhibitory effect has yet been described. However, it 
has been suggested that peptides with angiotensin-converting enzyme inhibitory function 
show some common features. First, the interaction between different inhibitory peptides 
and the angiotensin-converting enzyme is strongly influenced by the C-terminal tripeptide 
residues of the substrate, which interacts with the active sites of the enzyme [167]. The 
inhibitory potency of the peptides is further attributed by the hydrophobic (e.g. proline) as 
well as the positive charged (e.g. arginine and lysine) amino acids in the C-terminal end 
[168]. Additionally, the model of angiotensin-converting enzyme inhibition involves 
interaction, not only to the active site but also to the anionic inhibitor binding sites, which 
are different from the catalytic sites of the enzyme.  
6. Synergy between milk proteins and conventional antiviral drugs 
A combination of human lactoferrin with recombinant murine interferon-γ resulted in 
synergistic suppressive effects on disease progression in friend virus complex infected mice 
[56]. The experiment concluded that natural killer cell activity decreased by friend virus 
complex, and that the cellular activity returned to normal levels and survival rates increased 
upon treatment with lactoferrin and interferon-γ. Another study also supporting immune 
cell regulation by lactoferrin was performed by Spadaro et. al. In this study the anticancer 
activity of a recombinant form of human lactoferrin, talactoferrin-alfa (Agennix, Houston, 
TX) was evaluated. Talactoferrin-alfa was administered orally to BALB/c mice and the 
results showed an increase in the intestinal mucosal interferon-γ production, CD8+ T-cell 
cytotoxicity and the Peyer’s patch cellularity which included expansion of CD8+ T 
lymphocytes and nature killer T-cells, whereas no such phenomena were showed in 
interferon-γ knockout mice [169]. Thus, the inhibition of friend virus complex infection and 
tumor growth by lactoferrin/talactoferrin-alfa seems to be mediated by an interferon-γ-
dependent enhancement of CD8+ T-cells and natural killer T-cell activity, leading to 
diversified functions like antiviral defence, immune activation and cell growth regulation 
[170-173]. 
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Also, combined pre-infection administration of lactoferrin with post-infection 
administration of Ribavirin on Vero E6 cells could completely inhibit focus formation 
during hantavirus infection (similar to the traditional plaque formation). This combination 
therapy also demonstrated significantly increased survival rates in an in vivo mice model, 
not particularly surprising as lactoferrin inhibits viral adsorption to cells and Ribavirin 
interferes with viral RNA synthesis [122]. Moreover, the antiviral synergy of 
lactoferrin/lactoferricin with Cidofovir, Ribavirin, Zidovudine, and Acyclovir as all been 
well documented against human cytomegalovirus, hepatitis C virus, human 
immunodeficiency virus 1 and herpes simplex virus, respectively [13, 174-176]. 
Although it is known that lactoferrin has been used to inhibit initial viral infection by 
interfering with viral attachment and/or entry, the mode of antiviral activity against lots of 
viruses needs to be clarified in the future, e.g. the infection with hepatitis G virus in human 
MT-2C T-cells was prevented by bovine lactoferrin with no clear mechanism [63]. With 
regard to friend virus complex infection, most researchers have confirmed that human 
lactoferrin has anti-friend virus complex activity in a mouse leukemia model [57, 64], but 
have no direct effect on friend virus complex infection in vitro, indicating a mechanism 
involving immune regulationg rather than direct viral affects. They discovered that human 
lactoferrin prolonged survival rates and decreased viral titres in the spleen of infected mice 
by administering human lactoferrin intraperitoneally in the early phase of friend virus 
complex infection. Probably, the anti-friend virus complex mechanism of human lactoferrin 
related to the regulation on the myelopoiesis [64], which should be verified thoroughly.  
7. Commercial potential of milk derived proteins and peptides 
Immune regulation. There is emerging evidence that the utility of many immune mediators 
originating from milk represents novel therapeutic approaches depending on their activity 
of immune stimulation, immune suppression and induction of immunological tolerance. 
Hence, milk-derived proteins and peptides with immune modulating activity are claimed to 
be a health enhancing nutritional dietary supplement in functional food and pharmaceutical 
preparations. For instance, Colostrinin from bovine colostrum have demonstrated possible 
efficacy against various illnesses including viral infections, and ailments characterized by an 
overactive immune system, such as allergies, autoimmune diseases, neurodegenerative 
diseases like Alzheimer’s disease, etc. Capsules or chewable tablets containing Colostrinin 
are sold as an over the counter dietary supplement and are available in many countries in 
the world under names like Colostrinin, MemoryAid, Cognisure, Cognase, Cognate and 
Dyna (ReGen Therapetutics Limited, London, England) [151]. Moreover, whey proteins are 
used as common ingredients in various products including infant formulas, specialized 
enteral and clinical protein supplements, sports nutrition products, and specific weight 
management- and mood control products.  
Additionally, synthetic peptides derivatives tailored on natural milk proteins or fragments 
there of, may be another powerful way for design of immune regulating pharmaceutical 
candidates. For example, synthetic peptides tailored from milk proteins have been shown to 
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enhance proliferation of human peripheral blood lymphocytes. In particular, two fragments 
(YG and YGG), of bovine α-lactalbumin (fraction 18-19 and 18-20) can significantly stimulate 
the lymphocyte proliferation, while β-casomorphin-7 and β-casokinin-10, corresponding to 
fragments 60-66 and 193-202 of bovine β-casein, respectively, suppresses lymphocyte 
proliferation at low concentrations while enhanced proliferation at high concentrations [1] 
(Table 3).  
Recent studies have shown that synthetic innate defence regulator peptides offer protection 
by enhancing innate immune defenses of the host while suppressing potentially harmful 
excessive inflammatory response triggered by the invading pathogen. For example, innate 
defence regulator peptide 1 was chemotactic for T-helper cells type 1 [23], monocytes [27] 
and neutrophil response [28], acting in a mitogen-activated protein kinase-dependent 
manner, while reducing pro-inflammatory cytokine responses. Another peptide, innate 
defence regulator 1002, induces chemokines in human peripheral blood mononuclear cells 
[24] which prevents the production of interleukin-1β-induced matrix metalloproteinase 3 
and monocyte chemotactic protein-1 and selectively suppresses the inflammatory response 
[25]. 
With the aid of computational molecular modeling technologies, theoretical prediction of 
immune regulatory peptides has become available and practical. For example, RDP58, a 
novel d-amino acid decapeptide (r-(nle)3-r-(nle)3-gy-CONH2), which was developed by 
computer-aided rational based design on human leukocyte antigen-derived peptides [177], 
has been discovered to suppress the T-helper 1 cytokine profile, decrease production of 
inflammatory cytokines including tumor necrosis factor-α, interferon-γ, interleukin-2 and 
interleukin-12 in both cell lines and animal models [26, 178, 179]. Several clinical trials on 
human including phase I safety in normal volunteers, phase II mild-moderate active 
ulcerative colitis, phase II moderate active ulcerative colitis and phase IICrohn’s disease had 
been completed (Genzyme Corporation; Sanofi, Bridgewater, NJ). Moreover, quantitative 
structure-activity relationship analysis has been done for peptide design and optimization in 
developing novel antimicrobial drugs [180-183], and the numerical improvements of 
quantitative structure-activity relationship studies has been exemplified recently [184], 
though there are limitations to the predictive ability of the models [185, 186] this technology 
clearly accelerates lead peptide discovery.  
Suppression of immunological functions by milk derived proteins is thought to be 
important in the ontogeny of the neonatal gastrointestinal immune system, specifically by 
ensuring a state of tolerance with respect to food proteins. Kulkarni and Karlsson has 
demonstrated the essential role of milk-derived immunosuppressive factors (i.e. growth 
factor-β) during early development, and that neonatal mice deficient in transforming 
growth factor-β remain viable only as long as they receive maternal milk containing this 
same growth factor [187].  
Also, it is envisaged that most of the potential immunosuppressive activity of milk-derived 
peptides would be effective on chronic inflammatory diseases and organ transplant patients 
by decreasing allergy, autoimmunity, and organ rejection. For example, lactoferrin could 
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enhance the production of anti-inflammatory factors, like interleukin-11, not only in a 
hepatitis mouse model, but also in human intestinal myofibroblasts [188]. Additionally, 
hydrolysis of caseins with L. casei GG-derived enzymes has generated molecules with 
suppressive effects on lymphocyte proliferation and benefited the intestinal bacteria in the 
down-regulation of hypersensitivity reactions to ingested proteins in patients with food 
allergy [189]. Furthermore, two synthesized analogs of the hexapeptide of human β-casein 
(fraction 54-59) with modification at the N-terminal region not only showed inhibition in 
alloantigen inducing lymphocyte proliferation and production of interferon-γ in a SRBC 
mice model, but also demonstrated increased production of interleukin-4 and improved the 
skin graft survival. Thus, these peptides might serve as good templates for development of 
safe and effective immunosuppressant drugs [17]. Similarly, two other synthetic β-casein 
peptides HLPLP and WSVPQPK, have demonstrated potent antioxidant activity and 
inhibitory activity of angiotensin-converting enzyme [190]. Accordingly, proteins and 
peptides from milk could potentially be used in production of immune stimulating- and 
immunosuppressant agents for both prophylaxis and treatment of infectious diseases and 
immune related illnesses. 
Antiviral therapy. Lactoferrin might be a useful addition to conventional antiretroviral 
therapy, as traditional therapy supplemented with lactoferrin has demonstrated a more 
effective increase in CD4+ cell count than either treatments alone [191]. A potential oral 
vaccine resulting in expression of enterovirus 71 VP1 capsid protein in a transgenic animal 
system, under the control of an α-lactalbumin promoter and an α-casein leader sequence has 
demonstrated protection against enterovirus 71 [192]. Also, the combined treatment with 
human lactoferrin and recombinant murine interferon-γ on feline calicivirus infection might 
be of significance as a potential therapy for patients with leukemia and those infected with 
retroviruses [56].  
Most of the proteins and peptides with antiviral potential has also demonstrated synergy 
with conventional antiviral drugs, reducing the dose of the antiviral drugs, and limiting the 
development of drug-resistant viruses on account of the selective targeting of the host rather 
than infectious pathogens. At the present time, many peptides with immune regulating 
effects have been approved for clinical use against virus infection, such as Zadaxin, IM862, 
SCV-07 and so on [193]. Similarly, two peptide inhibitors of interleukin-10 may be applied to 
increase anti-hepatitis C virus immune response by restoring the immune stimulatory 
capabilities of dendritic cells, which have been suppressed by high levels of interleukin-10 
[194]. Moreover, candidacidal activities of a synthetic peptide from human lactoferrin fraction 
1-11 and 21-31 have been investigated for killing of multidrug-resistant pathogens [195-199]. 
Present research results, such as phase I safety and tolerability trials of human lactoferrin by 
AM Pharma [22], indicate that human lactoferrin 1-11 acts by selectively stimulating the innate 
immune system [200]. Thus, human lactoferrin 1-11 is more likely to be an interesting 
candidate for further exploration in various clinical tests, such as coating for dental or bone 
implants, in biosensing applications or in radiopharmaceutical therapy [199]. 
Vaccine adjuvant. Vaccine adjuvants, such as an immune potentiator or immunomodulator, 
have been used for decades to improve the immune response to vaccine antigens. This 
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involves presentation of the antigen to the immune system, regulation of both quantitative 
and qualitative aspects of the immune responses, targeting of specific cells, etc. Many 
adjuvants had been developed in the past, but were never accepted for routine vaccination 
because of safety concerns, such as acute toxicity and the possibility of delayed side effects. 
Thus, novel vaccine adjuvants without side effects should be proposed. Despite numerous 
publications on milk proteins and milk derived peptides with immune regulating activity, 
there are scarse reports of their adjuvant potential to vaccine. Lactoferrin could function as 
an effective adjuvant as it has been documented to enhance efficacy of the Bacillus Calmette-
Guerin, the current vaccine for tuberculosis disease by promoting host protection and 
decreasing disease manifestation [201, 202]. Additionally, recombinant porcine lactoferrin 
significantly increased serum IgA, IgG and infectious bursal disease virus-specific antibody, 
as well as enhanced interferon-γ and interleukin-12 expressed in chicken T-lymphocytes, 
suggesting that porcine lactoferrin could enhance cell-mediated immunity and strengthen 
the ability of vaccinating against infectious bursal disease infection [203, 204]. 
An innate defence regulator peptide, HH2, has shown synergy with oligonucleotides 
containing CpG motifs, when used as an immunoadjuvant to enhance the immune response 
through stimulation of T-helper 1 and T-helper 2 responses in newborn piglets which were 
vaccinated with a pseudorabies attenuated virus vaccine [29]. Recently, Brown et. al. found 
that the combination of oligonucleotides contain CpG motifs and HH2 displayed robust 
adjuvant effects on induction of T-helper 1 cellular immune response in mice by formulating 
with a booster recombinant Chlamydia antigen subunit vaccine [205]. Another synthetic 
peptide, WKYMVm, originally identified as a peptide that stimulated the activity of 
monocytes, neutrophils and dendritic cells [206-210], has demonstrated to selectively 
enhance the vaccine-induced CD8+ T-cell responses in a dose-dependent manner, in terms 
of interferon-γ secretion and cytolytic activity when it was co-delivered with human 
immunodeficiency virus, hepatitis B virus and influenza virus vaccines [211]. It is indicated 
that WKYMVm may function as a novel adjuvant for DNA vaccine. 
Cancer inhibition. More recently, a widely-read article focused on the amazing cases in which 
milk proteins and derived peptides were used in the treatment of different kinds of cancers. 
Whey protein is superior to other dietary proteins for suppression of tumour development 
in animal models usually for colon and mammary tumorigenesis [212]. Furthermore, 
lactoferrin and its peptides, for example, lactoferricin [212-214], both possess anticancer 
activity by inducing apoptosis; inhibit angiogenesis, modulating the carcinogen 
metabolizing enzymes, and so on. Casein and casein derived peptides have antimutagenic 
properties, and other whey protein components, such as β-lactoglobulin, α-lactalbumin and 
serum albumin, have also demonstrated anticancer potential [212, 215-217]. Moreover, a 
recombinant adenovirus containing the human lactoferrin cDNA has been constructed and 
its effects against tumor growth have been investigated in mice bearing EMT6 breast cancer. 
The results showed that recombinant delivery of human lactoferrin cDNA could induce 
apoptosis of the tumor cells by triggering the mitochondrial-dependent pathway and 
activation of caspase 3, suggesting that this recombinant cDNA delivery might be a 
promising drug strategy for breast cancer gene therapy [218].  
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In addition, the synthetic peptide, P60 (RDFQSFRKMWPFFAM) [219], has demonstrated 
potential of inhibiting the immunosuppressive activity of murine and human derived 
regulatory T-cells and enhances the effector T-cell stimulation in vitro by binding to 
regulatory T-cells specific forkhead or winged helix transcription factor 3. Thus, P60 can 
improve the immunogenicity of cancer and viral vaccines against CT26 tumor challenge and 
hepatitis C virus infection. Also, the in vivo antitumoral effects of LTX-302, a 9-mer peptide 
derived from bovine lactoferricin, have been examined by intratumoral injection. The results 
showed that LTX-302 induced tumor necrosis and infiltration of inflammatory cells followed 
by complete regression of the tumors, as it results in long term and specific cellular 
immunity against the A20 B-cell lymphoma that is CD4+ and CD8+ T-cells dependent [20]. 
8. Conclusion 
Most of the milk proteins and peptides that have been identified with antiviral properties 
are broad spectrum components targeting general features and mechanismes involved in a 
viral infection cycle. Hence, many of these milk proteins do also demonstrate synergy with 
conventional antiviral drugs. Recently, the diverse immunomodulatory activities of milk 
proteins/peptides have illustrated these molecules interesting potential as antiviral 
therapeutics, though the precise mechansiems of immune regulation needs to be thoroughly 
described. Although the synthetic peptides usually are shorter than natural proteins, the 
antiviral immune regulating properties of many of these synthetic derivatives appear to be 
similar as for the entire proteins. Thus we would argue that milk proteins and peptides, 
have great potential to serve as templates for design of more potent antiviral drugs. With 
proper scientific effort these molecules may have great therapeutic potential as supplements 
for current antiviral and anticancer therapy, as novel vaccine adjuvants for both human and 
far animals, and as immunosuppressants for autoimmune diseases and allergy treatment.  
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